Overview

* STAAR Surgical ( STAA ) Q2 net sales of $44.3 mln beat analyst expectations

* Net loss of $16.8 mln, influenced by restructuring charges

* Sales outside China rose 10% Y/Y, offsetting declines in China

Outlook

* Company not hosting conference call due to Alcon acquisition

* STAAR Surgical ( STAA ) notes ongoing cost optimization efforts

Result Drivers

* CHINA INVENTORY REDUCTION - Planned reduction in channel inventory in China led to 55% Y/Y decrease in net sales

* SALES EXCLUDING CHINA - Sales outside China rose 10% Y/Y, partially offsetting overall revenue decline

* COST OPTIMIZATION - Ongoing cost optimization efforts contributed to reduced operating expenses

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $44.32 $40.10

mln mln (9

Analysts

)

Q2 EPS -$0.34

Q2 Net -$16.81

Income mln

Q2 Gross 74.0%

Margin

Q2 Gross $32.80

Profit mln

Q2 -$29.96

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for STAAR Surgical Co ( STAA ) is $20.00, about 35.1% below its August 5 closing price of $27.02

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)